GKOS

Company Overview — What Does GLAUKOS Corp Do?

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. GLAUKOS Corp (GKOS) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Thomas W. Burns and employs approximately 780 people, headquartered in SAN CLEMENTE, California. With a market capitalization of $6.5B, GKOS is one of the notable companies in the Healthcare sector.

GLAUKOS Corp (GKOS) Stock Rating — Reduce (April 2026)

As of April 2026, GLAUKOS Corp receives a Reduce rating with a composite score of 41.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GKOS ranks #1,978 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, GLAUKOS Corp ranks #210 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GKOS Stock Price and 52-Week Range

GLAUKOS Corp (GKOS) currently trades at $116.40. The stock lost $3.05 (2.6%) in the most recent trading session. The 52-week high for GKOS is $130.23, which means the stock is currently trading -10.6% from its annual peak. The 52-week low is $73.16, putting the stock 59.1% above its annual trough. Recent trading volume was 522K shares, suggesting relatively thin trading activity.

Is GKOS Overvalued or Undervalued? — Valuation Analysis

GLAUKOS Corp (GKOS) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 10.18x, versus the sector average of 2.75x. The price-to-sales ratio is 14.50x, compared to 1.66x for the average Healthcare stock.

At current multiples, GLAUKOS Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

GLAUKOS Corp Profitability — ROE, Margins, and Quality Score

GLAUKOS Corp (GKOS) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -11.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -8.4% versus the sector average of -33.1%.

On a margin basis, GLAUKOS Corp reports gross margins of 77.6%, compared to 71.5% for the sector. The operating margin is -18.9% (sector: -66.1%). Net profit margin stands at -16.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 39.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GKOS Debt, Balance Sheet, and Financial Health

GLAUKOS Corp has a debt-to-equity ratio of 36.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.69x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $98M.

GKOS has a beta of 1.21, meaning it is more volatile than the broader market — a $10,000 investment in GKOS would be expected to move 21.3% more than the S&P 500 on any given day. The stability factor score for GLAUKOS Corp is 51/100, reflecting average volatility within the normal range for its sector.

GLAUKOS Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, GLAUKOS Corp reported revenue of $461M and earnings per share (EPS) of $-3.28. Net income for the quarter was $-75M. Gross margin was 77.6%. Operating income came in at $-84M.

In FY 2025, GLAUKOS Corp reported revenue of $507M and earnings per share (EPS) of $-3.28. Net income for the quarter was $-188M. Gross margin was 55.7%. Revenue grew 32.3% year-over-year compared to FY 2024. Operating income came in at $-200M.

In Q3 2025, GLAUKOS Corp reported revenue of $134M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-16M. Gross margin was 78.4%. Revenue grew 38.1% year-over-year compared to Q3 2024. Operating income came in at $-16M.

In Q2 2025, GLAUKOS Corp reported revenue of $124M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-20M. Gross margin was 78.3%. Revenue grew 29.7% year-over-year compared to Q2 2024. Operating income came in at $-23M.

Over the past 8 quarters, GLAUKOS Corp has demonstrated a growth trajectory, with revenue expanding from $96M to $461M. Investors analyzing GKOS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GKOS Dividend Yield and Income Analysis

GLAUKOS Corp (GKOS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GKOS Momentum and Technical Analysis Profile

GLAUKOS Corp (GKOS) has a momentum factor score of 52/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 23/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

GKOS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, GLAUKOS Corp (GKOS) ranks #210 out of 838 stocks based on the Blank Capital composite score. This places GKOS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GKOS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GKOS vs S&P 500 (SPY) comparison to assess how GLAUKOS Corp stacks up against the broader market across all factor dimensions.

GKOS Next Earnings Date

No upcoming earnings date has been announced for GLAUKOS Corp (GKOS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GKOS? — Investment Thesis Summary

The quantitative profile for GLAUKOS Corp suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 30/100 indicates premium valuation.

In summary, GLAUKOS Corp (GKOS) earns a Reduce rating with a composite score of 41.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GKOS stock.

Related Resources for GKOS Investors

Explore more research and tools: GKOS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GKOS head-to-head with peers: GKOS vs AZN, GKOS vs SLGL, GKOS vs VMD.